Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
Thiogenesis Therapeutics, and Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing disulfides that drive the production of critically important ...